Duopharma expects the supply of insulin to the MOH to continue after contract expiry in December 2019.
KUALA LUMPUR: CGS-CIMB Equities Research is maintaining its Add call for Duopharma
Biotech with an unchanged target price of RM1.56, which is pegged to its five-year historical mean of 16 times 2020F P/E).
It said on Friday Duopharma is optimistic the Ministry of Health (MOH) drug procurement contract will be extended beyond 2019F, thus ensuring steady public sector contribution.
Already a subscriber? Log in.
Limited time offer:
Just RM5 per month.
Cancel anytime. No ads. Auto-renewal. Unlimited access to the web and app. Personalised features. Members rewards.
Follow us on our official WhatsApp channel for breaking news alerts and key updates!
